6th Annual MarketsandMarkets Net-Gen Immuno-Oncology Conference

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening remarks from the Chairman	08:55 - 09:00
New Antibody Formats & Cellular Therapy
Keynote: Immuno-oncology Continues to Transform Oncology Therapeutics Roy Baynes, Executive Vice President, Chief Medical Officer, Eikon Therapeutics	09:00 - 09:30
Validated FOXP3 methylation panel to profile culture-induced epigenetic changes at Treg-specific loci Sarah Miller, Senior Research Associate, EpigenDx	09:30 - 10:00
Evaluating Efficacy of Novel Antibody and Cell-Based Therapeutics with Next-Generation Mouse Models Jenna Frame, Senior Scientist, Scientific Communications, Biocytogen	10:00 - 10:30
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:30 - 11:15
Challenges and Opportunities for Immuno-oncology (IO) and Antibody Drug Conjugates (ADC) Therapeutics To Treat Cancers Rakesh Dixit, CEO, Bionavigen	11:15 - 11:45
Veracyte Biopharma Atlas, a comprehensive cancer reference database Peter Russo, Director, Business Development, Biopharma, Veracyte	11:45 - 12:15
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	12:15 - 12:45
Lunch and Poster Presentations \| One-to-One Networking Meetings	12:45 - 13:45
Deciphering the role of natural killer cells in breast cancer Isaac Chan, Assistant Professor, UT Southwestern	13:45 - 14:15
Sanyou Biopharmaceuticals - Global leading integrated R&D service platforms for innovative biologics research Jin Qiu, Director, Business Development, Sanyou Bio	14:15 - 14:45
Search for “right” molecule and “right” dose: Case Studies from immuno-oncology portfolio Ayse Meric Ovacik, Senior Principal Scientist, Genentech	14:45 - 15:15
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:15 - 16:00
Targeted mRNA for in vivo Reprogrammed off-the-shelf CAR-T Therapies Dharini Shah, Senior Research Director, Immunology, Sanofi	16:00 - 16:30
SpliceIO- a robust platform for the discovery and validation of Splicing- derived neoantigens Gayatri Arun, Vice President, Envisagenics	16:30 - 17:00
Evaluating clinical and pharmacodynamic data of CLL patients treated with ibrutinib and an ADCC- enhanced anti-BAFF-R antibody (VAY736) Nadia Hassounah, Principal Scientist, Novartis	17:00 - 17:30
Closing remarks from the Chairman	17:30 - 17:30
End of Day 1 followed by Drinks Reception and Networking	17:30 - 17:30

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening remarks from the Chairman Alem Truneh, Co-founder & Chief Technology Officer, ImCheck Therapeutics	08:55 - 09:00
New Immune Checkpoints, Biomarker and Tumour Microenvironment
Targeting Immune Stimulants to Myeloid Cells For Cancer Immunotherapy Christopher Garris, Assistant Professor, Massachusetts General Hospital, Harvard Medical School	09:00 - 09:30
Elucidation of the Cellular and Molecular Features of the TME Underlying Immune Escape and IO Failure Alexander Bagaev, Vice President, Product Development, BostonGene	09:30 - 10:00
Disease monitoring with comprehensive genomics provides evidence of mechanism of action and immune evasion in patients receiving an individualized neoantigen cancer vaccine Matt Davis, Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.	10:00 - 10:30
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:30 - 11:15
How humanized mice reinforce your preclinical immuno-oncology research Dan Georgess, Chief Scientific Officer, TransCure bioServices,	11:15 - 11:45
T-cell Receptor Profiling from low input RNA Samples using NGS Jonathan Shaffer, Director, R&D, Qiagen	11:45 - 12:15
Turning preclinical findings into clinic-ready biomarker assays to support the phase I/II of BT7480, a Bicycle tumor-targeted immune cell agonist® Heather Cohen, Director, Translational Sciences, Bicycle Therapeutics	12:15 - 12:45
Lunch and Poster Presentation \| One-to-One Networking Meetings	12:45 - 13:45
Next generation checkpoints beyond PD-1 and CTLA-4 Nindhana Paranthaman, Principal Medical Director Oncology, Genentech	13:45 - 14:15
Targeting Beta-Cantenin reprograms the tumor microenvironment & stimulates a robust anti-tumor immune response Bradlee Heckmann, Co-Founder, CSO, Asha Therapeutics	14:15 - 14:45
Oncolytic herpes simplex virus immunovirotherapy Samuel Rabkin, Professor, Harvard Medical School	14:45 - 15:15
Closing remarks from the Chairman Alem Truneh, Co-founder & Chief Technology Officer, ImCheck Therapeutics	15:15 - 15:15
End of Conference	15:15 - 15:15